



**Editor-in-Chief**  
Pedro T Ramirez (USA)

**Associate Editors**  
Antonio Gonzalez (Spain)  
Anna Fagotti (Italy)  
Michael Frumovitz (USA)  
Rene Pareja (Colombia)  
Anuja Jhingran (USA)

**Video Editor**  
Luis Chiva (Spain)

**Social Media Editor**  
Ane Gerda Zahl Eriksson (Norway)

**Managing Editor**  
Lindsey Struckmeyer (USA)

**Editorial Office**  
*International Journal of Gynecological Cancer*, BMJ Journals  
Two Hudson Square, 3rd Floor,  
Hoboken, NJ 07030 USA  
E: [ijgc@jeditorial.com](mailto:ijgc@jeditorial.com)

**Production Editor**  
Hannah Martin  
E: [production.ijgc@bmj.com](mailto:production.ijgc@bmj.com)

**Customer support**  
For general queries and support with  
existing and new subscriptions:  
W: [support.bmj.com](mailto:support.bmj.com)  
T: +44 (0)20 7111 1105  
E: [support@bmj.com](mailto:support@bmj.com)

Self-archiving and permissions  
W: [bmj.com/company/productservices/rights-and-licensing/](http://bmj.com/company/productservices/rights-and-licensing/)  
E: [bmj.permissions@bmj.com](mailto:bmj.permissions@bmj.com)

**Disclaimer:** The Editor of *International Journal of Gynecological Cancer* has been granted editorial freedom and *International Journal of Gynecological Cancer* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *International Journal of Gynecological Cancer* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *International Journal of Gynecological Cancer* does not imply endorsement. Neither *International Gynecologic Cancer Society* and *European Society of Gynaecological Oncology* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *International Journal of Gynecological Cancer* (except for liability which cannot be legally excluded).

**Copyright:** © 2020 IGCS and ESGO. All rights reserved; no part of this publication may be reproduced in any form without permission.

*The International Journal of Gynecological Cancer (IJGC)* is published by BMJ Publishing Group Ltd and typeset by Exeter Premedia Services Private Limited, Chennai, India.

## Lead article

**1657** Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)

*A Fagotti, M G Ferrandina, G Vizzielli, T Pasciuto, F Fanfani, V Gallotta, P A Margariti, V Chiantera, B Costantini, S G Alletti, F Cosentino, G Scambia*

## Editorial

**1665** Neoadjuvant chemotherapy for advanced ovarian cancer: the tail of the scorpion for radical debulking surgery?

*C Fotopoulou*

## COVID-19

**1667** Decrease in gynecological cancer diagnoses during the COVID-19 pandemic: an Austrian perspective

*I Tsubulak, E Reiser, G Bogner, E Petru, J Hell-Teutsch, A Reinthaller, C Weirather, T Weiss, S Bozsa, B Puschacher, M Hall, D Hittler, K Hrauda, E Thell, S Clauss, J Pozniak, S Alice, D Gangl, G Gamperl, C Ebner, K Knoll, K Leitner, A Schilcher, M Schinnerl, V Sigl, C Singer, T Aigmüller, B Hofstätter, C Marth*

## Vulvar Cancer

**1672** Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget's disease of the vulva

*M Bartoletti, R Mazzeo, M De Scordilli, A Del Fabro, M G Vitale, L Bortot, M S Nicoloso, S Corsetti, M Bonotto, S Scalone, G Giorda, R Sorio, C Andreatta, M L Meacci, R De Vivo, G Fasola, F Sopracordevole, F Puglisi*

## Cervical Cancer

**1678** HrHPV testing vs liquid-based cytology in cervical cancer screening among women aged 50 and older: a prospective study

*B Andersen, S H Njor, A M S Jensen, T Johansen, U Jeppesen, H Svanholm*

**1684** Non-invasive stereotactic ablative boost in patients with locally advanced cervical cancer

*S Dakwadi, A Echeverria, P Jhaveri, T Bui, N Waheed, D Tran, M Bonnen, M Ludwig*

**1689** Prediction scoring system based on clinicohematologic parameters for cervical cancer patients undergoing chemoradiation

*Y J Kim, Y S Kim, J W Shin, B Osong, S H Lee*

**1697** Incidence, prevalence, and factors associated with lymphedema after treatment for cervical cancer: a systematic review

*A F Bona, K R Ferreira, R B d M Carvalho, L C S Thuler, A Bergmann*

**1705** Tumor total lesion glycolysis and number of positive pelvic lymph nodes on pretreatment positron emission tomography/computed tomography (PET/CT) predict survival in patients with locally advanced cervical cancer

*M De Cuypere, P Lovinfosse, C Gennigens, J Hermesse, R Rovira, J Duch, F Goffin, R Hustinx, F Kridelka*

## Uterine Cancer

**1713** Laparoscopic sentinel node mapping with intracervical indocyanine green injection for endometrial cancer: the SENTIFAIL study – a multicentric analysis of predictors of failed mapping

*G Sozzi, F Fanfani, R Berretta, V A Capozzi, S Uccella, N Buono, V Giallombardo, M C Di Donna, G Monterossi, S Restaino, I Capasso, G Dinoi, G Scambia, V Chiantera*

**1719** Cost-effectiveness of robotic hysterectomy versus abdominal hysterectomy in early endometrial cancer

*E S Lundin, P Carlsson, N B Wodlin, L Nilsson, P Kjöhede*

**1726** Does iatrogenic tumor rupture during surgery have prognostic implications for the outcome of uterine sarcomas?

*V Benito, A Lubrano, L León, F Molano, B Pinar*

**1733** Phase 2 study of cetuximab (Erbix) in patients with progressive or recurrent endometrial cancer

*B M Slomovitz, A Chelariu-Raicu, K M Schmeler, K H Lu, D M Gershenson, J Wolf, R L Coleman*

- 1738** Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion

*J Son, L M Chambers, C Carr, C M Michener, M Yao, A Beavis, T-T Yen, R L Stone, S L Wethington, A N Fader, W C Burkett, D L Richardson, A S Staley, S Ahn, P A Gehrig, D Torres, S C Dowdy, M W Sullivan, S C Modesitt, C Watson, A Veade, J Ehrisman, L Havrilesky, A A Secord, A Loreen, K Griffin, A Jackson, A Viswanathan, S Ricci*

## Ovarian Cancer

- 1748** Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care



*C H Norell, J Butler, R Farrell, A Altman, J Bentley, C J Cabasag, P A Cohen, S Fegan, M Fung-Kee-Fung, C Gourley, N F Hacker, L Hanna, C K Høgdall, G Kristensen, J Kwon, O McNally, G Nelson, A Nordin, D O'Donnell, T Schnack, P H Sykes, E Zotow, S Harrison*

- 1757** BRCA testing in women with high-grade serous ovarian cancer: gynecologic oncologist-initiated testing compared with genetics referral



*S Piedimonte, J Power, W D Foulkes, E Weber, L Palma, A Schiavi, E Ambrosio, R Konci, L Gilbert, K Jardon, L Baret, X Zeng*

- 1762** Diagnostic accuracy of serum insulin-like growth factor-binding protein 2 for ovarian cancer

*P K A Prayudi, I N G Budiana, P D Mahayasa, I G N H W Surya, A A G P Wiradnyana, K Suwiyoga*

- 1768** Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer

*A Chelariu-Raicu, C Levenback, B Slomovitz, J Wolf, D C Bodurka, J J Kavanagh, C Morrison, D Gershenson, R Coleman*

- 1775** Base rate of ovarian cancer on algorithms in patients with a pelvic mass



*A L D Rolfsen, A A Dahl, A H Pripp, A Dørum*

- 1780** Low value of staging in detecting extraovarian occult metastasis in mucinous borderline ovarian tumors

*H-J Jung, J-Y Park, D-Y Kim, D-S Suh, J-H Kim, Y-M Kim, Y-T Kim, J-H Nam*

## Surgery

- 1784** Physical activity trajectories following gynecological cancer: results from a prospective, longitudinal cohort study



*S Fleming, T Jones, M Janda, D Vagenas, L Ward, H Reul-Hirche, C Sandler, A Obermair, S Hayes*

- 1791** A systematic review and meta-analysis of sarcopenia as a prognostic factor in gynecological malignancy

*E R Allanson, Y Peng, A Choi, S Hayes, M Janda, A Obermair*

- 1798** Comparison of surgical and pathological parameters after laparoscopic transperitoneal pelvic/para-aortic lymphadenectomies

*A Jacob, A Plaikner, A Schneider, G Favero, R Tozzi, P Mallmann, C Domröse, P Martus, S Marnitz, J Barinoff, C Kohler*

## Reviews

- 1803** Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes

*A Pietragalla, M Arcieri, C Marchetti, G Scambia, A Fagotti*

- 1811** Improving response to progestin treatment of low-grade endometrial cancer

*E Baxter, D J Brennan, J N McAlpine, J J Mueller, F Amant, M D J M van Gent, D G Huntsman, R L Coleman, S N Westin, M S Yates, C Krakstad, M A Quinn, M Janda, A Obermair*

## Clinical trials

- 1824** DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment



*M McMullen, K Karakasis, B Loembe, E Dean, G Parr, A M Oza*

- 1829** Sentinel lymph node biopsy versus pelvic lymphadenectomy in early-stage cervical cancer: a multi-center randomized trial (PHENIX/CSEM 010)

*H Tu, H Huang, B Xian, J Li, P Wang, W Zhao, X Chen, X Xie, C Wang, B Kong, J Xiao, P Zhang, J Liu, on behalf of the PHENIX Investigators and the CSEM group*

---

### Case study

- 1834** Management of low-grade serous ovarian neoplasm in the setting of fertility preservation

*Z Marchocki, M Rouzbahman, T Chawla, T May*

---

### Corners of the world

- 1840** Advancing gynecologic oncology in Latin America through Project ECHO

*M L Varon, E Baker, E E Estrada, K M Schmeler, R Pareja*

---

### Video articles

- 1842** Orthotopic continent urinary diversion (the Budapest pouch) in 10 steps

*M E Căpîlna, L Palfalvi, L Ungar, A Cozlea, S L Kiss, M Stanca*

- 1844** Tertiary cytoreductive surgery by laparoscopy in granulosa cell tumor recurrence

*V García Pineda, A Hernández, M Cabanes, J Siegrist, M Gracia, I Zapardiel*

- 1846** Laparoscopic complete resection of bulky precaval nodes by extraperitoneal approach in a patient with advanced endometrial cancer

*I Jaunarena, M Gorostidi, R Ruiz, C Villalain, P Cobas, A Lekuona*

---

### Commentary

- 1848** Effective approaches towards eliminating cervical cancer from low-and middle-income countries amid COVID-19 pandemic

*M S Rahman, M Gultekin, Z S Lassi*

---

### Letters

- 1850** More attention is needed for the corrigendum to the revised FIGO staging for carcinoma of the cervix uteri

*E P Olthof, C H Mom, J van der Velden*

- 1851** Tumor size in cervical cancer: an ongoing dilemma

*G Salvo, D Odetto, C Saenz Perrotta, F Noll, M Perrotta, R Pareja, A Wernicke, P T Ramirez*

---

### Miscellaneous

- 1852** Correction: *Clinical relevance of high–intermediate risk endometrial cancer according to European risk classification*

- 1853** Correction: *Location of recurrences in high-risk stage I endometrial cancer patients not given postoperative radiotherapy: A Danish gynecological cancer group study*